Whittier Trust’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Whittier Trust’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-79	Closed	-$9K	–	1351
2017 Q1	$9K	Buy	+79	New	+$9.22K	﹤0.01%	1030

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Whittier Trust's ICPT Position: Q2 2017 in Review

Whittier Trust sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2017, closing a stake of 79 shares — an estimated $9K sold.

Whittier Trust first reported a position in ICPT in Q1 2017 and held it in 1 quarter. The position peaked at $9K in Q1 2017. 167 funds tracked by Wall St. Rank hold ICPT as of Q2 2017.

Whittier Trust reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Whittier Trust sold 79 Intercept Pharmaceuticals, Inc. shares in Q2 2017, an estimated $9K.
Whittier Trust first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2017 and held it in 1 quarter.
Whittier Trust's Intercept Pharmaceuticals, Inc. position peaked at $9K in Q1 2017.
167 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2017.

Based on Whittier Trust's 13F filing for Q2 2017, filed 20 Jul 2017.